Gent, Belgium
Gent, Belgium

Innogenetics N.V. is an international in vitro diagnostics company, with headquarters in Ghent, Belgium. The company develops and markets IVD testing solutions from specialized manual testing to fully automated routine testing that cover areas such as infectious diseases, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone. The company was acquired in September 2010 by Japanese Fujirebio Inc., part of Miraca Holdings Inc., and changed name to Fujirebio Europe on October 1st 2013. The CEO of Fujirebio Europe N.V. is Christiaan De Wilde. Wikipedia.


Time filter

Source Type

The present invention provides a method for prediction of renal transplantation outcome, for assessment of the risk of post-transplantation kidney rejection, and/or for selecting an appropriate treatment, therapeutic agent or therapeutic agent dosage regime for the treatment of post-transplantation kidney rejection, whereby the presence and/or absence of at least one nucleic acid polymorphism in the gene for ficolin-2 of the kidney is detected. Further provided are oligonucleotides and kits for use in such method.


The current invention relates to a standardized method for amplification of an HCV NS5B nucleic acid fragment of any one of HCV genotypes 1 to 6 as a tool for analysis of sequence variations that may be correlated with HCV drug resistance.


Patent
Roche Holding AG and Innogenetics | Date: 2013-03-07

The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S rRNA genes, to be used for the specific detection and/or identification of Serratia species, in particular of Serratia marcescens, Serratia ficaria and/or Serratia fonticola, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Serratia species, in particular Serratia marcescens, Serratia ficaria and/or Serratia fonticola, using said new nucleic acid sequences derived from the ITS region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Serratia species in a sample.


Patent
Roche Holding AG and Innogenetics | Date: 2013-03-06

The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of Proteus species, in particular of Proteus mirabilis, Proteus vulgaris and/or Proteus penneri, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Proteus species, in particular Proteus mirabilis, Proteus vulgaris and/or Proteus penneri, using said new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Proteus species in a sample.


Patent
Innogenetics | Date: 2012-07-19

New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDDYSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.


The current invention relates to a standardized method for amplification of an HCV NS3/4A or NS3 nucleic acid fragment of any one of HCV genotypes 5 to 6 or HCV genotype 1 as a tool for analysis of sequence variations that may be correlated with HCV drug resistance.


The present invention is related to automated and semi-automated nucleic acid hybridizations and immuno-assays, and methods for performing nucleic acid hybridizations or immuno-assays on an integrated device. Specifically, this invention is an integrated device and method for performing solid support based nucleic acid hybridizations and immuno-assays.


The current invention relates to a standardized method for amplification of an HCV NS5B nucleic acid fragment of any one of HCV genotypes 1 to 6 as a tool for analysis of sequence variations that may be correlated with HCV drug resistance.


The present invention relates to the field of detection and genotyping of Human Papillomavirus (HPV) in clinical samples. More specifically, the present invention provides a combination of at least 11 SPF PCR primers for an unbiased and efficient detection of a broad selection of HPV genotypes, including all high-risk (HR) ones. The present invention further provides a method for HPV detection, using said PCR primer combination, that allows to select only HPV-positive samples for further steps of HPV identification.


Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.

Loading Innogenetics collaborators
Loading Innogenetics collaborators